Supriya Lifescience Reports Q2 Standalone Net Profit of ₹29.2 Crore Versus ₹50.4 Crore YoY

Market snapshot: Supriya Lifescience Ltd. announced its Q2 standalone financial results, reporting a net profit of ₹29.2 crore compared to ₹50.4 crore in the corresponding quarter of the previous fiscal year.

Data Snapshot

• Q2 standalone net profit stood at ₹29.2 crore, compared to ₹50.4 crore in the same quarter last year.
• Q1 FY27 standalone revenue was reported at ₹189.75 crore with a net profit of ₹24.04 crore.
• Prior year Q2 FY26 revenue reached ₹199.83 crore with profit after tax of ₹50.43 crore.

What's Changed

• Standalone net profit for Q2 decreased to ₹29.2 crore from ₹50.4 crore YoY.
• Sequential bottoming is observed compared to Q1 FY27 standalone net profit of ₹24.04 crore.

Key Takeaways

• Supriya Lifescience reported a YoY contraction in Q2 standalone net profit to ₹29.2 crore from ₹50.4 crore.
• The current quarter profit of ₹29.2 crore indicates sequential recovery from Q1 FY27 net profit of ₹24.04 crore.
• Global API sales across primary European and Asian markets continue to dictate earnings stability.

SAHI Perspective

The year-over-year earnings contraction reflects margin pressures and operational baseline comparisons relative to the previous fiscal year. However, sequential earnings show uptick from Q1 FY27 levels.

Market Implications

Market participants will assess therapeutic mix distribution across key product categories including anesthetics and vitamins alongside export performance in regulated markets.

Trading Signals

Market Bias: Bearish

Short-term market bias reflects cautious sentiment due to a year-over-year decline in standalone net profit to ₹29.2 crore from ₹50.4 crore.

Overweight: Active Pharmaceutical Ingredients

Underweight: API Exporters under margin contraction

Trigger Factors:

• Detailed quarterly operating margin and product mix disclosures
• Export volume momentum in European and Latin American markets

Time Horizon: Near-term (0-3 months)

Industry Context

Active Pharmaceutical Ingredient manufacturers face varying demand cycles across international regulated markets alongside raw material cost adjustments and shifting customer inventory dynamics.

Key Risks to Watch

• Input material price fluctuation affecting operating margins
• Geographic dependency on primary export destinations across Europe and Asia

Recent Developments

In Q1 FY27, Supriya Lifescience reported standalone revenue of ₹189.75 crore with a profit after tax of ₹24.04 crore.

Closing Insight

Monitoring second-half volume growth across core niche API products will provide clarity on full-year margin normalized trajectory.

High Performance Trading with SAHI.